STOCK TITAN

XOMA Royalty Corporation - XOMA STOCK NEWS

Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.

XOMA Corporation (NASDAQ: XOMA) is a biotechnology royalty aggregator that plays a pivotal role in accelerating the development of groundbreaking therapeutic candidates. With an extensive portfolio of over 70 assets, XOMA acquires potential future economics associated with pre-commercial and commercial therapeutic candidates licensed to pharmaceutical or biotech companies. This unique model enables XOMA to provide non-dilutive, non-recourse funding to its partners, helping them advance their internal drug candidates or cater to general corporate needs.

Notably, XOMA has pioneered in the discovery and development of antibody therapeutics, leading to over 20 licenses producing milestone and royalty payments in the future. One key asset in their portfolio is X358, an allosteric monoclonal antibody aimed at treating hyperinsulinism by reducing insulin receptor activity.

XOMA has recently expanded its portfolio through strategic acquisitions. In January 2024, the company acquired an economic interest in DSUVIA® (sufentanil sublingual tablet) from Talphera, Inc., for $8 million. DSUVIA® is an FDA-approved pain management option used in supervised medical settings. The agreement stipulates that XOMA will receive all royalties and milestones related to DSUVIA® until $20 million is accrued. Subsequently, royalties will be shared between XOMA and Talphera.

Further broadening its portfolio, XOMA acquired Kinnate Biopharma in April 2024, bringing additional assets into their royalty pipeline. Kinnate’s lead candidates include investigational pan-RAF inhibitor exarafenib and FGFR inhibitor KIN-3248, both targeting cancers with specific genetic alterations.

In April 2024, XOMA announced a $9 million milestone following the FDA approval of Day One Biopharmaceuticals’ OJEMDA™ (tovorafenib), designed to treat pediatric low-grade glioma harboring BRAF alterations. This approval marks a significant addition to XOMA's cash flow and royalty income.

Additionally, XOMA's economic interest in three of Daré Bioscience's women's health products, including the FDA-approved XACIATO™ (clindamycin phosphate) vaginal gel, Ovaprene®, and Sildenafil Cream, 3.6%, signifies their commitment to addressing underrepresented therapeutic areas with significant growth potential.

As of their latest financial results, XOMA reported strong cash reserves and a growing portfolio of commercial and development-phase assets, ensuring long-term sustainability and value creation for shareholders. The company’s disciplined approach to capital deployment and strategic acquisitions highlights its commitment to enhancing human health through biotechnology advancements.

Rhea-AI Summary

XOMA Corporation will have its CEO, Jim Neal, present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 10:00 AM ET. The conference aims to highlight XOMA's role as a biotechnology royalty aggregator, helping companies enhance human health by acquiring future economic rights linked to pre-commercial therapeutic candidates. A live stream of the presentation will be accessible here and on XOMA's website. A replay will be available for 90 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
conferences
-
Rhea-AI Summary

XOMA Corporation reported its second quarter 2022 financial results, achieving total revenues of $1.0 million, up from $0.9 million in Q2 2021. The net loss widened to $4.7 million compared to $2.2 million in the prior year. Cash at the end of June stood at $83.2 million, with no debt, which management believes will sustain operations for several years. The acquisition of Checkmate Pharmaceuticals resulted in a $2.5 million payment to XOMA, while Rezolute and Day One plan to advance to Phase 3 clinical trials, signaling positive progress in their pipelines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.64%
Tags
-
Rhea-AI Summary

XOMA Corporation (Nasdaq: XOMA) has announced cash dividends for holders of its Series A and B Cumulative Preferred Stock. Shareholders of the 8.625% Series A stock will receive $0.53906 per share, while holders of the 8.375% Series B stock will receive $0.52344 per depositary share. The dividends are scheduled for payment on July 15, 2022, to shareholders on record by July 1, 2022. XOMA plays a significant role as a biotechnology royalty aggregator, managing over 70 assets related to therapeutic candidates, providing crucial funding for biotech advancement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
dividends
Rhea-AI Summary

XOMA Corporation, a biotechnology royalty aggregator, announced that its Chairman and CEO, Jim Neal, will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 10:00 AM ET. The presentation will be accessible online and archived for 90 days post-event. XOMA focuses on acquiring potential future earnings from pre-commercial therapeutic candidates, providing non-dilutive funding to sellers. The company's portfolio includes over 70 assets associated with drug products in development, underscoring its impact on improving human health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
conferences
-
Rhea-AI Summary

XOMA Corporation (Nasdaq: XOMA) reported a strong financial performance for Q1 2022, with total revenues of $3.1 million, up from $0.4 million in Q1 2021. This increase was propelled by a $2 million milestone from Rezolute for the RZ358 study. The company concluded Q1 2022 with cash and restricted cash totaling $88.6 million and no debt. Notably, XOMA recognized a net loss of $2.3 million, a significant improvement compared to a $7.4 million loss in the prior year. The firm remains optimistic about its financial stability and future operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
-
Rhea-AI Summary

XOMA Corporation (Nasdaq: XOMA) announced cash dividends for holders of its Series A and Series B Cumulative Preferred Stock. Holders of the 8.625% Series A Cumulative Preferred Stock (Nasdaq: XOMAP) will receive $0.53906 per share, while holders of depositary shares representing 1/1000 of the Series B Cumulative Preferred Stock (Nasdaq: XOMAO) will receive $0.52344 per share. The dividends will be paid on or about April 15, 2022, to shareholders on record as of April 1, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
dividends
Rhea-AI Summary

On March 10, 2022, XOMA Corporation (Nasdaq: XOMA) announced that Chairman and CEO Jim Neal will present at Oppenheimer’s 32nd Annual Healthcare Conference on March 17, 2022, at 12:40 PM ET. This virtual event can be accessed through a direct link or via the investor relations section of XOMA's website, where a replay will be available for 90 days. XOMA specializes in acquiring future royalties from pre-commercial therapeutic candidates, providing non-dilutive funding to biotech companies. The company has an extensive portfolio with over 70 assets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
conferences
-
Rhea-AI Summary

XOMA Corporation (Nasdaq: XOMA) reported a strong financial performance in 2021, earning $36.2 million in milestone payments and achieving positive operating cash flow for the second consecutive year. Key highlights include a $35 million milestone from its Anti-TGFβ Antibody License Agreement with Novartis. Total revenues reached $38.2 million in 2021, up from $29.4 million in 2020. The company ended the year with $95.4 million in cash and no debt. Significant advances include commercialization approval for a bispecific antibody and progress in multiple drug candidates. CEO succession planning is underway.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.47%
Tags
-
Rhea-AI Summary

XOMA Corporation, a biotechnology royalty aggregator, announced that its Chairman and CEO, Jim Neal, will participate in a fireside chat at the 42nd Annual Cowen Health Care Conference. The event is scheduled for March 7, 2022, at 1:30 PM ET. Investors can access the presentation live or via a replay on the company's website for 90 days post-event. XOMA plays a crucial role in advancing human health by acquiring potential future economics from pre-commercial therapeutic candidates, boasting a portfolio of over 70 assets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
conferences
Rhea-AI Summary

XOMA Corporation (Nasdaq: XOMA) announced that its CEO, Jim Neal, will present at the Aegis Capital Corp Virtual Conference on February 24, 2022 at 11:00 AM ET. This event runs from February 23-25, 2022, showcasing biotech advancements. The presentation will be accessible via Aegis and on XOMA's investor relations website, with a replay available for 90 days. XOMA, a biotechnology royalty aggregator, specializes in acquiring future economics linked to drug candidates, helping biotech firms with funding to advance their projects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
conferences

FAQ

What is the current stock price of XOMA Royalty Corporation (XOMA)?

The current stock price of XOMA Royalty Corporation (XOMA) is $27.13 as of December 20, 2024.

What is the market cap of XOMA Royalty Corporation (XOMA)?

The market cap of XOMA Royalty Corporation (XOMA) is approximately 302.6M.

What does XOMA Corporation do?

XOMA Corporation is a biotechnology royalty aggregator that acquires potential future economics from pre-commercial and commercial therapeutic candidates licensed to pharmaceutical or biotech companies.

What is XOMA’s business model?

XOMA provides non-dilutive, non-recourse funding to biotech companies in exchange for future economic rights to their therapeutic candidates, helping these companies advance their drug development.

What recent acquisitions has XOMA made?

In 2024, XOMA acquired an economic interest in DSUVIA® from Talphera, Inc., and Kinnate Biopharma, expanding its portfolio with new commercial and development-phase assets.

What are some key assets in XOMA's portfolio?

Key assets include DSUVIA® for pain management, OJEMDA™ for pediatric low-grade glioma, and women's health products like XACIATO™, Ovaprene®, and Sildenafil Cream from Daré Bioscience.

How does XOMA generate revenue?

XOMA generates revenue through milestone and royalty payments from the assets and therapeutic candidates it holds economic interests in.

What is the significance of XOMA’s investment in X358?

X358 is an allosteric monoclonal antibody that reduces insulin receptor activity, potentially having a major impact on the treatment of hyperinsulinism.

How does XOMA support biotech companies?

XOMA supports biotech companies by providing non-dilutive funding, allowing them to advance their drug candidates or support corporate initiatives without giving up equity.

What was the financial impact of XOMA’s acquisition of DSUVIA®?

XOMA will receive 100% of royalties and milestones from DSUVIA® sales until $20 million is accrued, after which royalties are shared with Talphera.

Who are some of XOMA’s partners?

XOMA has partnerships with various biotech and pharmaceutical companies, including Talphera, Alora Pharmaceuticals, Viracta Therapeutics, and Daré Bioscience.

What are XOMA's future plans for growth?

XOMA plans to continue its disciplined approach to capital deployment, acquiring economic interests in promising therapeutic candidates, and building a sustainable, cash-generating royalty portfolio.

XOMA Royalty Corporation

Nasdaq:XOMA

XOMA Rankings

XOMA Stock Data

302.58M
11.68M
0.84%
65.62%
1.11%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
EMERYVILLE